JPM
62
2
T
39
-6
PNR
62
-4
DE
40
-2
XOM
40
-2
FLR
59
4
YUM
38
2
VRTX
43
-4
BF.B
29
-2
ZTS
36
7
USB
46
-2
MCD
54
4
MAC
62
-3
NUE
50
2
INTC
36
8
ORLY
54
-3
PM
60
-8
WFC
71
-3
VTR
46
-3
ABBV
59
-3
JPM
62
2
T
39
-6
PNR
62
-4
DE
40
-2
XOM
40
-2
FLR
59
4
YUM
38
2
VRTX
43
-4
BF.B
29
-2
ZTS
36
7
USB
46
-2
MCD
54
4
MAC
62
-3
NUE
50
2
INTC
36
8
ORLY
54
-3
PM
60
-8
WFC
71
-3
VTR
46
-3
ABBV
59
-3
Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Sell
50

DNLI
Denali Therapeutics

Last Price:
27.45
Seasonality Move:
18.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Denali Therapeutics Price Quote

$27.45
+0.40 (+1.48%)
(Updated: November 4, 2024 at 3:50 PM ET)

Denali Therapeutics Key Stats

Sell
50
Denali Therapeutics (DNLI) is a Sell
Day range:
$26.27 - $27.49
52-week range:
$14.56 - $32.13
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
11.79
P/B ratio:
2.79%
Volume:
837.2K
Avg. volume:
701K
1-year change:
42.14%
Market cap:
$3.9B
Revenue:
$330.5M
EPS:
$-2.85

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Is Denali Therapeutics Cash Flow Positive?

  • What Is DNLI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$390.9M
  • What Is Denali Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $514.2M
  • What Is Denali Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$180.7M

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 14.95%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 41.15
Upside from Last Price: 52.14%

Major Shareholders

  • How many DNLI shares are owned by institutional investors?
    240.7M DNLI shares are owned by institutional investors
  • How many DNLI shares are owned by insiders?
    2.7M DNLI shares are owned by insiders